Feldan Therapeutics secures $16.5 million series B to bring lead asset to clinical development

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, recently announced the initial closing of a $16.5 million Series B investment. The funds will primarily be used to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.

Feldan Therapeutics presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Innovation Factory announces innovators in i.d.e.a Fund™ cohort 2

Next

$11 million program supporting Ontario’s biotech start-ups